Stay updated on Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial
Sign up to get notified when there's something new on the Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial page.

Latest updates to the Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdministrative updates: Revision: v3.4.2 was added, while Revision: v3.4.1 and a government funding/status notice were removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding lapse notice at the top with a link to opm.gov, and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedUI/metadata updates include showing the glossary, adding 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', and removing or altering older labels ('Last Update Submitted that met QC Criteria' and 'Revision: v3.3.4') as well as changes to 'No FEAR Act Data'.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No substantive study information or documents were changed.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations sections were reorganized: a main Locations section added with state subheadings (California, Illinois, New York, North Carolina, Ohio) and the prior state-specific sections removed; the page revision notes show an update from v3.3.2 to v3.3.3.SummaryDifference0.6%

- Check92 days agoChange DetectedPublication note now states that PubMed entries are automatically filled and may not pertain to the study, and the revision tag has been updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial page.